



The Cyclodextrin Company

Getting the best out of Cyclodextrins

CYCLOLAB Ltd.


Company Introduction and Technology Presentation





Inclusion complex formation

- Sub-nanometer size cavities
 αCD 0.57 nm, βCD 0.78 nm, γCD 0.95 nm
- Primary (bottom) and secondary (top) OH groups are exposed to the solvent
- Hydrophobic cavity / Somewhat hydrophilic outer surface
- Inclusion complex formation with hydrophobic molecules → solubilizing

Non-covalent "host-guest" type interaction Reversible









The Cyclodextrin Company Consequences of CD complexation

Cyclodextrins may increase

Cyclodextrins may decrease

Drug solubility

Drug stability

Wetting, dissolution rate

Absorbed quantity

Taste

Smell

Side effect

Irritation



CDs used in pharmaceuticals

Oral solution



Itraconazole (Janssen) HP-β-CD

Eye drops



Indomethacin (Bausch&Lomb) HP-β-CD



Diclofenac (Novartis) HP-y-CD

Nasal



Estradiol (Servier) RM-β-CD

Oral tablets/capsules



Piroxicam (Chiesi) β-CD



Ziprasidone (Pfizer) SBE-β-CD



Cladribine (Merck) HP-β-CD



Ethinylestradiol/Drospirenon (Bayer) β-CD



CDs used in pharmaceuticals

Intravenous



Voriconazole (Sandoz) SBE-β-CD



Carfilzomib (Amgen) SBE-β-CD



Amiodarone (Baxter) SBE-β-CD

Topical



Minoxidil (Pierre Fabre) v-CD

Taste masking



Cetirizine (J&J) β-CD



Nicotine (Nicorette) β-CD

Veterinary



Maropitant for dogs (Pfizer) SBE-6-CD



Itraconazole for cats (Elanco) HP-β-CD







The world's only all-round Cyclodextrin Service Provider

Experience

CycloLab started as a spin-off of Sanofi-Aventis Chinoin Pharma (1989)
Over 40-year experience in all fields of CD-technology

- over 480 technical/scientific papers
- over 900 technical reports to our customers
- ~ 200 different cyclodextrin derivatives
- ~ 120 patents/applications
- ~ 40 products on the market (5 of them drugs)
- Drug Master Files (USA type IV) and eCTD
- Over 20,000 citations to CYCLOLAB's papers

Expertise & Technology

Custom synthesis

Drug Solubilization, stabilization

Other industrial applications

Cyclodextrin-related analytics, stability testing

GMP-conform manufacturing



Cyclolab's evolution



ISO 9001 certificate

Research and development studies, exploring potential in CDs (1975-)

Spin-off company, establishment (1989) Establishment of a smaller GMP facility (2002)

DMF accepted by the FDA (2008)

Development of a proprietary technology for SBECD production (2006-2008)

Audited and approved by the Hungarian Pharmaceutical Regulatory Authority (2007)

Dedicated GMP
plant established
for the SBECD
production
(2010)

EudraGMDP
registration
(2014), Annual
capacity for
SBECD is over
15,000 kgs (2017)

Successful regulatory inspection (OGYÉI) and obtaining cGMP license for Dexolve (2018)



Team and resources



Team

- 16 qualified cyclodextrin scientists
 - 11 PhDs
 - 2 MBAs
 - 2 members in the QA
 - By profession
 - chemists
 - chemical engineers
 - biologists
 - pharmacists
- 12 qualified technicians and operators
- Sales, business dev, logistics, admin

Resources

2,000 m² (own property) facility

- 2 galenic/technology labs
- 3 analytical labs (GC, HPLC and CZE)
- 2 synthetic chemistry labs
- 150 m² cGMP compliant clean room
- 350 m² cGMP compliant production area (Spray-drying unit)
- Freeze-drying units

Quality systems

ISO 9001:2015 cGMP (OGYÉI/57792-7/2018) US FDA DMF Type IV






GMP Manufacturing

Betadex Sulfobutyl
Ether Sodium

DEXOLVETM


Custom cGMP synthesis of CDs,
CD complexes,
investigational
medicinal products

Preparation/filing of regulatory dossier




















Related services – R&D

Early phase drug development

Customization of CD enabled formulations: Investigation of changes in physico-chemical properties: Life cycle management

Custom cyclodextrin synthesis

Exclusive manufacture, unique synthetic routes, self-tailored products and characteristics

In vitro bioequivalence studies

Design and performance of in vitro studies to support bioequivalence of a CD enabled formulation.

CD-guest interaction studies

Method development,

HPLC, GC, CE, UV, MS, NMR, IR, Micro and BET content

Assay. Analytical services *impurity* tests

validation; cGMP release testing of pharma grade CDs; methods: Stability studies

> **Bioanalytical** investigations

CD-based chiral

IP services and consultation

separations

Over 62.000 CD related papers

30 years of experience in compilation of CD related patents (synthesis, application, etc), patent claim analysis, consultancy in CD related projects





Sugammadex

Our main efforts are driven into technical and analytical support for companies developing generic Bridion and supply of a wide variety of process impurities

Formulation development

Cyclolab is actively developing formulations to improve performance of known compounds in the pharma and other industries

<u>Pipeline</u>

Selective drug delivery systems

Attaching targeting moieties to CDs to develop selective DDSs for cancer therapies

NCE Cyclodextrins

Developing CDs as actives for diseases such as cancer, cardiovascular diseases, neurodegenerative illnesses or as life-saving antidotes

CDs as new class of antibiotics

A family of CD molecules that may prevent Quorum sensing of bacteria in combination products and as single APIs

CDs in biological formulations

CDs to be applied as artificial chaperones in mAb and other protein formulations to control folding and prevent aggregation, improve stability, replacing detergents



Thank you for the attention

